Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies-a joint review from endocrinologists and cardiologists

Acta Diabetol. 2023 Apr;60(4):471-480. doi: 10.1007/s00592-022-02018-3. Epub 2022 Dec 20.

Abstract

There is accumulating evidence that novel glucose-lowering agents infer potent cardiovascular and renal benefits. Therefore, it is imperative to reassess the management of post-transplant diabetes mellitus and consider the role of newer agents. With improved transplant-related survival and high prevalence of post-transplant diabetes, management of long-term complications such as diabetes are increasingly important. There are limited guidelines to assist in choice of appropriate agents after solid organ transplantation. Traditional therapies including insulin and sulfonylureas may still have a role; however, other agents should be considered prior. The evidence of novel glucose-lowering agents in post-transplant care is limited, and most studies have focused on kidney transplant recipients. While there are some parallels between renal and cardiac transplant recipients, the potential cardiovascular benefits, particularly on cardiac fibrosis are unique to cardiac transplantation. The treatment of diabetes, with a focus on additional cardiac and renal benefits, needs to be brought to the forefront of post-transplant care with incorporation of recent evidence outside of transplantation. The role for novel glucose-lowering agents in cardiac transplant recipients will be explored, with a summary of available evidence.

Keywords: Cardiac transplant; GLP-1; Heart transplant; Post-transplant diabetes mellitus; SGLT2.

Publication types

  • Review

MeSH terms

  • Cardiologists*
  • Diabetes Mellitus* / drug therapy
  • Diabetes Mellitus* / etiology
  • Diabetes Mellitus, Type 2* / complications
  • Endocrinologists
  • Glucose
  • Heart Transplantation* / adverse effects
  • Humans

Substances

  • Glucose